Estradiol

Estradiol is the principal intracellular human estrogen and an FDA-approved drug across multiple distinct formulations. Oral, transdermal, vaginal, valerate, and cypionate records are not interchangeable.

tier S · libido · 5 route or ester records kept separate

verdict

Estradiol is established therapy for labeled menopause and hypoestrogenism indications. The useful question is not whether estradiol works in the abstract, but which molecule, route, formulation, population, and risk context the claim describes.

the core tension

Estradiol has strong clinical evidence, but broad hormone claims become misleading when they erase route, ester, indication, uterine status, or the exact comparator used in a study.

what it is

17-beta estradiol is an endogenous steroid hormone and estrogen-receptor ligand. Prescription forms include unesterified estradiol and distinct ester prodrugs.

what it does

Estradiol binds estrogen receptors and regulates estrogen-responsive tissues and pituitary gonadotropin feedback. Clinical effects and risks depend on route, systemic exposure, indication, and whether endometrial protection is needed.

origin

The base hormone is endogenous. The reviewed products include oral micronized estradiol, a systemic transdermal patch, a vaginal insert, and separate intramuscular valerate and cypionate oil esters.

does it work

Yes, for its labeled indication and formulation. Route matters: observational VTE evidence differed between oral and transdermal estrogen, and a crossover study found a hepatic first-pass marker effect with oral conjugated estrogen but not transdermal estradiol. Neither study makes every estrogen product equivalent.

key facts

• molecular formula: C18H24O2 (17-beta estradiol base)
• molecular weight: 272.38 g/mol (17-beta estradiol base)
• amino acids: n/a (steroid hormone, not a peptide)
• half-life: formulation-dependent; no single value transfers across oral, transdermal, vaginal, valerate, and cypionate products
• type: endogenous steroid estrogen and estrogen-receptor ligand
• CAS: 50-28-2
• 5 separate formulation or ester records shown
• 271 first-VTE cases in ESTHER
• 21 participants in the randomized route-marker crossover study

frequently asked questions

Are oral, transdermal, and vaginal estradiol the same exposure?

No. They are separate formulations and routes. The vaginal insert is locally administered but still has systemic absorption; the patch is systemic through skin; the tablet undergoes oral handling.

Are estradiol valerate and estradiol cypionate interchangeable?

No. They are distinct ester molecules in distinct intramuscular oil products. Neither ester should inherit the other's release profile.

Why does having a uterus matter?

Unopposed systemic estrogen increases endometrial-cancer risk in a person with a uterus. Product labeling discusses adding a progestogen to reduce endometrial-hyperplasia risk.

Is transdermal estrogen proven risk-free?

No. ESTHER found different VTE associations by route in a specific observational population, not zero risk for every person or product.

What is estradiol's half-life?

There is no single page-wide number. Oral, transdermal, vaginal, valerate, and cypionate products have different absorption and release behavior, so the page leaves a cross-formulation half-life blank.

related peptides

• testosterone: separate hormone entry; estradiol evidence remains route- and ester-specific

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.